EMA To Tackle Inconsistencies In Quality Data For Drug-Device Combinations
The European Medicines Agency believes guidance is needed on the quality aspects of drug-device combinations to show that these products are appropriately designed and can be used correctly in their intended clinical situations.
You may also be interested in...
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.